HealthCap
HealthCap
  • About
    • Our Story
    • Strategy
    • Partners
    • Team
    • Special Advisors
  • Our Commitment
    • ESG Policy
  • Investments
    • Portfolio Companies
    • Approved Products
  • News
    • Portfolio Companies
    • HealthCap
  • Contact & Legal
    • Contact Us
    • Privacy Policy
    • Cookie Policy
  • LinkedIn
  • Twitter
  • Wikipedia
HealthCap

HealthCap is a family of venture capital funds investing globally in life sciences. With more than EUR 1 billion raised since the start in 1996, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.

Read more

Portfolio Companies News

  • January 13, 2021
    GenSight Biologics Announces Public...

    Bilateral improvement in visual acuity from a unilateral injection of gene therapy – consistent with REVERSE trial findings Significant improvement against visual acuity nadir Paris, France, January 13, 2021, 7:30 am CET – GenSight Biologics (Euronext: SIGHT, I... read more

  • January 7, 2021
    CARISMA Therapeutics Completes Seri...

    PHILADELPHIA, Jan. 7, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that it has completed its Series B equity financing providing for gross proceeds of $47 million, bringing CARISMA'... read more

  • January 6, 2021
    Spruce Biosciences Provides Corpora...

    -CAHmelia Adult Classic CAH Program Underway in U.S. and Europe- -Initiation of Phase 2 Pediatric Classic CAH Program Anticipated in Second Half of 2021- -Initiation of Phase 2 Polycystic Ovary Syndrome Program Anticipated in Second Half of 2021- -New Patent Issuance Extends Tildacerfont Patent E... read more

  • January 6, 2021
    Strongbridge Biopharma plc Announce...

     Expects to Report KEVEYIS® (dichlorphenamide) Fourth Quarter 2020 Revenue of Approximately $8.2 Million and Full-Year 2020 Revenue of Approximately $30.7 Million, a 41.5 Percent Increase over 2019 Revenue of $ $21.7 Million ~ ~ Targets Full-Year 2021 KEVEYIS® (dichlorphenamide) Revenue G... read more

  • January 6, 2021
    Targovax grants IOVaxis 3 months ex...

    COVID-19 have caused delays to submission and processing of the regulatory application to initiate clinical development in China Due to the unforeseen delays, Targovax has extended the term of IOvaxis´s license option by 3 months, otherwise the agreement remains unchanged Oslo, Norway 6 ... read more

HealthCap Info

  • November 03, 2020
    Q3 2020 General Market Overview

Facts

  • 118

    Since the start in 1996, HealthCap funds have invested in 118 portfolio companies.

    Read more
  • 46

    46 of the portfolio companies have been taken public on nine different markets.

    Read more
  • 26

    26 of the portfolio companies’ pharmaceutical products have been approved for marketing.

    Read more
  • 12

    Unicorn Factory
    Since the start in 1996, HealthCap has helped build 12 companies with a valuation of USD 1 billion or more.

    Read more

Twitter

GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Oph… @HealthCapVC
2 days ago
CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immu… @HealthCapVC
8 days ago

Subscribe to news

Venture Capital for Breakthrough Therapies

This site uses cookies. But first we need your consent. More info.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close